Alice Melão,  —

A mechanism that cells normally use to keep them healthy was found to have a dual role in amyotrophic lateral sclerosis (ALS). While the process, called autophagy, delays disease progression in early stages, it contributes to ALS’s deadly spread through the spinal cord in later stages. This study, “…

Wave Life Sciences is developing two ALS and frontotemporal dementia therapies that target a gene mutation common in both. The therapies target mutations of the C9orf72 gene, Wave said in a business update. “I am excited to announce our next development program targeting C9orf72 mutations in ALS and FTD,” Dr.

Worldwide Clinical Trials was selected as the Clinical Research Organization (CRO) to run a Phase 3 study of the investigational stem-cell therapy NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm Cell Therapeutics, which developed NurOwn, expects the collaboration will provide all of the necessary requirements to pursue the placebo-controlled,…

Radicava (edaravone), the first approved treatment for amyotrophic lateral sclerosis in 22 years, is being welcomed with “a great deal of excitement” in the ALS community, an ALS Association executive said. The excitement stems both from Radicava’s potential to treat the disease and the hope that its approval will lead…

Below is a transcript of the ALS News Today interview with Calaneet Balas, executive vice president of strategy for the ALS Association. The nonprofit association, established in 1985, is active in promoting research into ALS, providing assistance to patients through its network of 39 state chapters, and in coordinating care though its…

Edaravone — now more widely known by its U.S. brand name, Radicava — has produced “a minor miracle” for some amyotrophic lateral sclerosis patients, said Stephen Byer, co-director of ALS Worldwide. “We have found and continue to find great benefit in terms of slowing, stopping and, in some…

Stem cell transplantation in patients with amyotrophic lateral sclerosis (ALS) has the potential to be “an important alternative strategy” in treating the disease, a new study suggests. In recent decades, many advances in identifying and understanding the underlying mechanisms of ALS have been made. But those advances have not resulted in…

Researchers have identified the sequence of molecular events leading to motor neuron death in amyotrophic lateral sclerosis (ALS), an important step forward that may lead to new therapies to halt this process. They found that unlike healthy astrocytes, which are…

Radicava, also known by its generic name edaravone, is the first treatment approved by U.S. Food and Drug Administration (FDA) in more than two decades to help amyotrophic lateral sclerosis (ALS) patients. While awaiting its arrival, ALS News Today spoke to the company responsible for its U.S. launch,…

Researchers at Ben-Gurion University (BGU) believe that an existing FDA-approved anti-cancer drug, rituximab, could be modified and used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. In lab studies with mice, the therapy restored resident immune cells of the central nervous system, which could indicate…